T790M突变与EGFR-TKI耐药后治疗策略

被引：2

作者：

王迪 ^{[1
]}

甄春英 ^{[2
]}

刘宝刚 ^{[1
]}

机构：

[1] 哈尔滨医科大学附属第三医院

[2] 哈尔滨市胸科医院

来源：

现代肿瘤医学 | 2015年 / 23卷 / 19期

关键词：

T790M; 非小细胞肺癌; EGFR-TKI; 耐药;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100214 ;

摘要：

表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)治疗非小细胞肺癌已获得较好的疗效,患者生活质量明显改善。但EGFR-TKI耐药似乎成为了靶向治疗的瓶颈,耐药的产生可能存在多种机制,包括T790M突变、K-ras基因突变、C-Met基因扩增、BRAF基因突变、BIM多态性缺失、EML4-ALK融合基因突变及上皮间充质转化等,其中最常见的是T790M基因突变。目前研究表明,T790M基因还可能具有一定预测疗效和预后的作用。本文将简要介绍T790M基因的发现、起源、作用机制及预后,并主要针对EGFR-TKIs耐药后的治疗策略进行综述。

引用

页码：2871 / 2874

页数：4

共 14 条

[1] Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients [J].

Kuiper, J. L. ;

Heideman, D. A. M. ;

Thunnissen, E. ;

Paul, M. A. ;

van Wijk, A. W. ;

Postmus, P. E. ;

Smit, E. F. .

LUNG CANCER, 2014, 85 (01) :19-24

[2]

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients[J] . Wei Li,Shengxiang Ren,Jiayu Li,Aiwu Li,Lihong Fan,Xuefei Li,Cao Zhao,Yayi He,Guanghui Gao,Xiaoxia Chen,Shuai Li,Jingyun Shi,Caicun Zhou,Ke Fei,Gerald Schmid-Bindert.Lung Cancer . 2014

[3] Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer [J].

Ono, Naomi ;

Yamazaki, Toshikazu ;

Tsukaguchi, Toshiyuki ;

Fujii, Toshihiko ;

Sakata, Kiyoaki ;

Suda, Atsushi ;

Tsukuda, Takuo ;

Mio, Toshiyuki ;

Ishii, Nobuya ;

Kondoh, Osamu ;

Aoki, Yuko .

CANCER SCIENCE, 2013, 104 (10) :1346-1352

[4]

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial[J] . Yi-Long Wu,Jin Soo Lee,Sumitra Thongprasert,Chong-Jen Yu,Li Zhang,Guia Ladrera,Vichien Srimuninnimit,Virote Sriuranpong,Jennifer Sandoval-Tan,Yunzhong Zhu,Meilin Liao,Caicun Zhou,Hongming Pan,Victor Lee,Yuh-Min Chen,Yan Sun,Benjamin Margono,Fatima Fuerte,Gee-Chen Chang,Kasan Seetalarom,Jie Wang,Ashley Cheng,Elisna Syahruddin,Xiaopin

[5] Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors [J].

Yu, Helena A. ;

Sima, Camelia S. ;

Huang, James ;

Solomon, Stephen B. ;

Rimner, Andreas ;

Paik, Paul ;

Pietanza, M. Catherine ;

Azzoli, Christopher G. ;

Rizvi, Naiyer A. ;

Krug, Lee M. ;

Miller, Vincent A. ;

Kris, Mark G. ;

Riely, Gregory J. .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) :346-351

[6]

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations[J] . Kenichi Nishie,Tomoya Kawaguchi,Akihiro Tamiya,Tomoyasu Mimori,Naoko Takeuchi,Yoshinobu Matsuda,Naoki Omachi,Kazuhiro Asami,Kyoichi Okishio,Shinji Atagi,Tomohisa Okuma,Akihito Kubo,Yoshihito Maruyama,Shinzoh Kudoh,Minoru Takada.Journal of Thoracic Oncology . 2012 (11)

[7] Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype [J].

Metro, Giulio ;

Chiari, Rita ;

Duranti, Simona ;

Siggillino, Annamaria ;

Fischer, Matthias J. ;

Giannarelli, Diana ;

Ludovini, Vienna ;

Bennati, Chiara ;

Marcomigni, Luca ;

Baldi, Alice ;

Giansanti, Michele ;

Minotti, Vincenzo ;

Crino, Lucio .

LUNG CANCER, 2012, 78 (01) :81-86

[8]

Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations[J] . Kazuhiro Asami,Tomohisa Okuma,Tomonori Hirashima,Masaaki Kawahara,Shinji Atagi,Tomoya Kawaguchi,Kyoichi Okishio,Naoki Omachi,Naoko Takeuchi.Lung Cancer . 2012

[9]

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J] . Jin-Ji Yang,Hua-Jun Chen,Hong-Hong Yan,Xu-Chao Zhang,Qing Zhou,Jian Su,Zhen Wang,Chong-Rui Xu,Yi-Sheng Huang,Bin-Chao Wang,Xue-Ning Yang,Wen-Zhao Zhong,Qiang Nie,Ri-Qiang Liao,Ben-Yuan Jiang,Song Dong,Yi-Long Wu.Lung Cancer . 2012

[10]

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial[J] . Journal of Clinical Oncology . 2012 (17)

← 1 2 →